Loading…

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution

Abstract Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE). We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi. Additional chromo...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genetics and cytogenetics 2010-06, Vol.199 (2), p.139-142
Main Authors: Falchi, Lorenzo, Rege-Cambrin, Giovanna, Fava, Carmen, Donti, Emilio, Luzi, Debora, Giugliano, Emilia, Gubbiotti, Marta, Schippa, Monica, Liberati, Anna Marina
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503
cites cdi_FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503
container_end_page 142
container_issue 2
container_start_page 139
container_title Cancer genetics and cytogenetics
container_volume 199
creator Falchi, Lorenzo
Rege-Cambrin, Giovanna
Fava, Carmen
Donti, Emilio
Luzi, Debora
Giugliano, Emilia
Gubbiotti, Marta
Schippa, Monica
Liberati, Anna Marina
description Abstract Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE). We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi. Additional chromosomal abnormalities appeared during the course of disease in seven cases, being present at diagnosis in three. A total of 6/10 (60%) patients achieved complete cytogenetic remission (CCyR) with imatinib in 3–14 months. Major or complete molecular remission (CMR) was obtained in four CCyR patients after 21, 25, 22, and 12 months, as well as in a fifth patient who started nilotinib because of suboptimal response after 75 months of imatinib treatment. One patient received nilotinib due to imatinib intolerance after 56 months of therapy while on CMR, and maintained such status. After a median follow-up of 82 months (range, 3–116), six patients are alive, five of which are in continuous CCyR while one patient is in his third CCyR on dasatinib after relapsing on imatinib and nilotinib. Five patients are in complete (four) or major (one) molecular remission, ongoing at 3, 48, 61, 95, and 96 months, on imatinib (three) or nilotinib (two). Although a small number of patients was studied, our results suggest that long-term cytogenetic and molecular remission can be achieved in CML CE patients with TKis treatment.
doi_str_mv 10.1016/j.cancergencyto.2010.02.008
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_745936201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165460810000622</els_id><sourcerecordid>733118679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503</originalsourceid><addsrcrecordid>eNqNUl2L1DAULaK44-pfkIAPPnXMR5u2CIIs6wcs-LD6HG7TO05mMs2YpLP0L_krvXVWQV_0KXByzj3cc25RvBB8LbjQr3ZrC6PF-BVHO-ewlpx-uFxz3j4oVqJtVFlVtX5YrIhdl5Xm7UXxJKUd57yRnX5cXEheNaIW7ar4fjulDG7EgR2CRzt5iCziwaXkwpgYRGRgtw5P0Htkdy5vWZ5jSCRhezdCQubGretdDpHlLUY4zoSwI2SHY05nid3GMDrLDjP64AbmcdqTCTAYBwbD4DK5gWfLQrQXZuJa_xPCU_DT8v20eLQBn_DZ_XtZfHl3_fnqQ3nz6f3Hq7c3pa10l8u266XedFoqHJRWA0LT14C9sqpu-q6WG9lCNVS9BE0Qb7sNQRIq3XMUNVeXxcvz3GMM3yZM2VAaFr2HEcOUTFPVndKU-r-ZSgnR6qYj5usz01J0KeLGHKM7QJyN4GZp1ezMH62apVXDpaFWSf383mfqDzj81v6qkQjXZwJSLieH0SRL6VscXESbzRDcfxq9-WuO9Y56A7_HGdMuTJEqSUaYRAJzuxzYcl-CTotrKdUPCCjVmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733118679</pqid></control><display><type>article</type><title>Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Falchi, Lorenzo ; Rege-Cambrin, Giovanna ; Fava, Carmen ; Donti, Emilio ; Luzi, Debora ; Giugliano, Emilia ; Gubbiotti, Marta ; Schippa, Monica ; Liberati, Anna Marina</creator><creatorcontrib>Falchi, Lorenzo ; Rege-Cambrin, Giovanna ; Fava, Carmen ; Donti, Emilio ; Luzi, Debora ; Giugliano, Emilia ; Gubbiotti, Marta ; Schippa, Monica ; Liberati, Anna Marina</creatorcontrib><description>Abstract Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE). We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi. Additional chromosomal abnormalities appeared during the course of disease in seven cases, being present at diagnosis in three. A total of 6/10 (60%) patients achieved complete cytogenetic remission (CCyR) with imatinib in 3–14 months. Major or complete molecular remission (CMR) was obtained in four CCyR patients after 21, 25, 22, and 12 months, as well as in a fifth patient who started nilotinib because of suboptimal response after 75 months of imatinib treatment. One patient received nilotinib due to imatinib intolerance after 56 months of therapy while on CMR, and maintained such status. After a median follow-up of 82 months (range, 3–116), six patients are alive, five of which are in continuous CCyR while one patient is in his third CCyR on dasatinib after relapsing on imatinib and nilotinib. Five patients are in complete (four) or major (one) molecular remission, ongoing at 3, 48, 61, 95, and 96 months, on imatinib (three) or nilotinib (two). Although a small number of patients was studied, our results suggest that long-term cytogenetic and molecular remission can be achieved in CML CE patients with TKis treatment.</description><identifier>ISSN: 0165-4608</identifier><identifier>EISSN: 1873-4456</identifier><identifier>DOI: 10.1016/j.cancergencyto.2010.02.008</identifier><identifier>PMID: 20471518</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Benzamides ; Chronic myeloid leukemia ; Clone Cells - drug effects ; Clone Cells - pathology ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Imatinib Mesylate ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Medical Education ; Middle Aged ; Piperazines - therapeutic use ; Protein Kinase Inhibitors - therapeutic use ; Pyrimidines - therapeutic use ; Remission Induction ; Treatment Outcome</subject><ispartof>Cancer genetics and cytogenetics, 2010-06, Vol.199 (2), p.139-142</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>Copyright 2010 Elsevier Inc. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503</citedby><cites>FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20471518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Falchi, Lorenzo</creatorcontrib><creatorcontrib>Rege-Cambrin, Giovanna</creatorcontrib><creatorcontrib>Fava, Carmen</creatorcontrib><creatorcontrib>Donti, Emilio</creatorcontrib><creatorcontrib>Luzi, Debora</creatorcontrib><creatorcontrib>Giugliano, Emilia</creatorcontrib><creatorcontrib>Gubbiotti, Marta</creatorcontrib><creatorcontrib>Schippa, Monica</creatorcontrib><creatorcontrib>Liberati, Anna Marina</creatorcontrib><title>Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution</title><title>Cancer genetics and cytogenetics</title><addtitle>Cancer Genet Cytogenet</addtitle><description>Abstract Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE). We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi. Additional chromosomal abnormalities appeared during the course of disease in seven cases, being present at diagnosis in three. A total of 6/10 (60%) patients achieved complete cytogenetic remission (CCyR) with imatinib in 3–14 months. Major or complete molecular remission (CMR) was obtained in four CCyR patients after 21, 25, 22, and 12 months, as well as in a fifth patient who started nilotinib because of suboptimal response after 75 months of imatinib treatment. One patient received nilotinib due to imatinib intolerance after 56 months of therapy while on CMR, and maintained such status. After a median follow-up of 82 months (range, 3–116), six patients are alive, five of which are in continuous CCyR while one patient is in his third CCyR on dasatinib after relapsing on imatinib and nilotinib. Five patients are in complete (four) or major (one) molecular remission, ongoing at 3, 48, 61, 95, and 96 months, on imatinib (three) or nilotinib (two). Although a small number of patients was studied, our results suggest that long-term cytogenetic and molecular remission can be achieved in CML CE patients with TKis treatment.</description><subject>Adult</subject><subject>Benzamides</subject><subject>Chronic myeloid leukemia</subject><subject>Clone Cells - drug effects</subject><subject>Clone Cells - pathology</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Karyotyping</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Medical Education</subject><subject>Middle Aged</subject><subject>Piperazines - therapeutic use</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Remission Induction</subject><subject>Treatment Outcome</subject><issn>0165-4608</issn><issn>1873-4456</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNUl2L1DAULaK44-pfkIAPPnXMR5u2CIIs6wcs-LD6HG7TO05mMs2YpLP0L_krvXVWQV_0KXByzj3cc25RvBB8LbjQr3ZrC6PF-BVHO-ewlpx-uFxz3j4oVqJtVFlVtX5YrIhdl5Xm7UXxJKUd57yRnX5cXEheNaIW7ar4fjulDG7EgR2CRzt5iCziwaXkwpgYRGRgtw5P0Htkdy5vWZ5jSCRhezdCQubGretdDpHlLUY4zoSwI2SHY05nid3GMDrLDjP64AbmcdqTCTAYBwbD4DK5gWfLQrQXZuJa_xPCU_DT8v20eLQBn_DZ_XtZfHl3_fnqQ3nz6f3Hq7c3pa10l8u266XedFoqHJRWA0LT14C9sqpu-q6WG9lCNVS9BE0Qb7sNQRIq3XMUNVeXxcvz3GMM3yZM2VAaFr2HEcOUTFPVndKU-r-ZSgnR6qYj5usz01J0KeLGHKM7QJyN4GZp1ezMH62apVXDpaFWSf383mfqDzj81v6qkQjXZwJSLieH0SRL6VscXESbzRDcfxq9-WuO9Y56A7_HGdMuTJEqSUaYRAJzuxzYcl-CTotrKdUPCCjVmA</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Falchi, Lorenzo</creator><creator>Rege-Cambrin, Giovanna</creator><creator>Fava, Carmen</creator><creator>Donti, Emilio</creator><creator>Luzi, Debora</creator><creator>Giugliano, Emilia</creator><creator>Gubbiotti, Marta</creator><creator>Schippa, Monica</creator><creator>Liberati, Anna Marina</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20100601</creationdate><title>Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution</title><author>Falchi, Lorenzo ; Rege-Cambrin, Giovanna ; Fava, Carmen ; Donti, Emilio ; Luzi, Debora ; Giugliano, Emilia ; Gubbiotti, Marta ; Schippa, Monica ; Liberati, Anna Marina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Benzamides</topic><topic>Chronic myeloid leukemia</topic><topic>Clone Cells - drug effects</topic><topic>Clone Cells - pathology</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Karyotyping</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Medical Education</topic><topic>Middle Aged</topic><topic>Piperazines - therapeutic use</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Remission Induction</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Falchi, Lorenzo</creatorcontrib><creatorcontrib>Rege-Cambrin, Giovanna</creatorcontrib><creatorcontrib>Fava, Carmen</creatorcontrib><creatorcontrib>Donti, Emilio</creatorcontrib><creatorcontrib>Luzi, Debora</creatorcontrib><creatorcontrib>Giugliano, Emilia</creatorcontrib><creatorcontrib>Gubbiotti, Marta</creatorcontrib><creatorcontrib>Schippa, Monica</creatorcontrib><creatorcontrib>Liberati, Anna Marina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Cancer genetics and cytogenetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Falchi, Lorenzo</au><au>Rege-Cambrin, Giovanna</au><au>Fava, Carmen</au><au>Donti, Emilio</au><au>Luzi, Debora</au><au>Giugliano, Emilia</au><au>Gubbiotti, Marta</au><au>Schippa, Monica</au><au>Liberati, Anna Marina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution</atitle><jtitle>Cancer genetics and cytogenetics</jtitle><addtitle>Cancer Genet Cytogenet</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>199</volume><issue>2</issue><spage>139</spage><epage>142</epage><pages>139-142</pages><issn>0165-4608</issn><eissn>1873-4456</eissn><abstract>Abstract Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE). We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi. Additional chromosomal abnormalities appeared during the course of disease in seven cases, being present at diagnosis in three. A total of 6/10 (60%) patients achieved complete cytogenetic remission (CCyR) with imatinib in 3–14 months. Major or complete molecular remission (CMR) was obtained in four CCyR patients after 21, 25, 22, and 12 months, as well as in a fifth patient who started nilotinib because of suboptimal response after 75 months of imatinib treatment. One patient received nilotinib due to imatinib intolerance after 56 months of therapy while on CMR, and maintained such status. After a median follow-up of 82 months (range, 3–116), six patients are alive, five of which are in continuous CCyR while one patient is in his third CCyR on dasatinib after relapsing on imatinib and nilotinib. Five patients are in complete (four) or major (one) molecular remission, ongoing at 3, 48, 61, 95, and 96 months, on imatinib (three) or nilotinib (two). Although a small number of patients was studied, our results suggest that long-term cytogenetic and molecular remission can be achieved in CML CE patients with TKis treatment.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20471518</pmid><doi>10.1016/j.cancergencyto.2010.02.008</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-4608
ispartof Cancer genetics and cytogenetics, 2010-06, Vol.199 (2), p.139-142
issn 0165-4608
1873-4456
language eng
recordid cdi_proquest_miscellaneous_745936201
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Benzamides
Chronic myeloid leukemia
Clone Cells - drug effects
Clone Cells - pathology
Female
Hematology, Oncology and Palliative Medicine
Humans
Imatinib Mesylate
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Medical Education
Middle Aged
Piperazines - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - therapeutic use
Remission Induction
Treatment Outcome
title Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A52%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20molecular%20remissions%20are%20achievable%20with%20tyrosine%20kinase%20inhibitor%20therapy%20in%20patients%20with%20chronic%20myeloid%20leukemia%20and%20additional%20cytogenetic%20clonal%20evolution&rft.jtitle=Cancer%20genetics%20and%20cytogenetics&rft.au=Falchi,%20Lorenzo&rft.date=2010-06-01&rft.volume=199&rft.issue=2&rft.spage=139&rft.epage=142&rft.pages=139-142&rft.issn=0165-4608&rft.eissn=1873-4456&rft_id=info:doi/10.1016/j.cancergencyto.2010.02.008&rft_dat=%3Cproquest_cross%3E733118679%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-89b26f9623ed363dea7b5aeb3c357b952f28a4d4b2a6c35089f2f22a46b0e1503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733118679&rft_id=info:pmid/20471518&rfr_iscdi=true